A German study of gastroenterologist and patient acceptance of biosimilars to treat ulcerative colitis (UC) and Crohn’s disease (CD) suggests that there is reluctance among patients to accept biosimilars, and a need for better communication with physicians and education about biosimilars. The study, published in PLOS, examined gastroenterologists’ motivations for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behavior, and explored patients’ attitudes to biosimilars.
In Germany 2 infliximab biosimilars were approved in 2013 (Remsima and Inflectra) and launched in 2015. A biosimilar for etanercept was approved in Europe in January 2016, and approval of other biosimilars that will be potential treatments for inflammatory bowel disease, is very likely to occur in the coming months and years. Other biosimilars, including those for adalimumab and rituximab, are also under development. The authors note that even though Germany has some of the highest market shares in the European biosimilars market, automatic substitution of bio-originators with biosimilars by pharmacists is not allowed and there is still a marked reluctance by physicians to prescribe biosimilars. Although regulatory requirements in Europe (and the United States) ensure that approved biosimilars have the same activity and safety profile as the originator drug and the quality of the production process is guaranteed, “concerns apparently remain,” the authors write.
The PLOS study used data from a cross-sectional study undertaken in 2015-2016, that involved 25 German gastroenterologists and 136 patients, aged 18 and over, who were being treated for UC (n = 67) or CD (n = 69). Biosimilars accounted for less than 15% of all biologic therapies—88% of gastroenterologists said they preferred to prescribe a reference biological rather than a biosimilar as first-line therapy. This decreased to 72% and 80% for UC and CD, respectively, for second line treatment.
Gastroenterologists were split into 3 groups: investigative (primarily concerned with symptom improvement/disease modification, conservative (primarily concerned with safety), and other (influenced primarily by other factors). Physicians managed at least 1 patient with each disease in each of the following patient groups:
A great majority (89%) of the investigative physicians and 100% of the conservative physicians said they prescribed biosimilars instead of bio-originators to gain experience with the new products. Forty-four percent of investigative physicians believed biosimilar efficacy is equivalent to the bio-originator, and said lower cost was a consideration; 83% of conservative physicians said lower cost and “economic prescribing” played a role in selecting biosimilars.
Patients, however, showed some reluctance toward using a biosimilar. The mean percentage of patients who accepted a biosimilar without reluctance, having never been prescribed a bio-originator or biosimilar, was 60%, versus 43% of patients currently receiving a bio-originator and with no clinical reason for a change in therapy. Of those being treated with biosimilars,
A small proportion of patients would not accept treatment with a biosimilar, only the bio-originator. Physicians reported that a small proportion (mean 8% to 9%) of patients refused any form of biologic therapy, regardless of the patient’s prior experience with biologic therapy or the reason for a switch in therapy.
The study authors noted that 2 recent surveys of European gastroenterologists conducted a year apart, following greater education and use of biosimilars, found increased confidence in the use of biosimilars and a spike in the number of doctors who considered biosimilars and reference biologics as interchangeable. Cost savings remained the primary objective with using biosimilars among more than 90% of physicians, and immunogenicity was the main concern for 69% of physicians.
The authors conclude that results from their study and other surveys of European gastroenterologists suggest that patient and physician communication is very important, and further education may be needed to determine the role of other factors in influencing the conversations.
“A cautious approach is needed until sufficient long-term data are available for biosimilars to mitigate any concerns that currently exist,” the authors write, and recommend more robust product identification mechanisms to ensure traceability and accurate pharmacovigilance for biosimilar products.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.